Roxane Laboratories, Inc. has announced the approval of their Abbreviated New Drug Application for Protriptyline HCl Tablets, USP, 5mg and 10mg. The product is available in bottles of 100 tablets for immediate shipment to wholesalers and pharmacies nationwide.Roxane Laboratories’ Protriptyline HCl Tablets, USP are AB rated to VIVACTIL(R) (protriptyline HCl). Annual sales of VIVACTIL(R) (protriptyline HCl) Tablets are approximately $11.3 Million.Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
Related Articles Read More >

Confidently navigate the transition from bench to batch

FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension

Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
